Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy.

Neo, Shu Hui; Lew, Qiao Jing; Koh, Ser Mei; Zheng, Lu; Bi, Xuezhi; Chao, Sheng-Hao

Neo, Shu Hui; Lew, Qiao Jing; Koh, Ser Mei; Zheng, Lu; Bi, Xuezhi; Chao, Sheng-Hao.

Affiliation

Neo SH; Expression Engineering and Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138668.
Lew QJ; Expression Engineering and Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138668.
Koh SM; Temasek Polytechnic, Singapore 529757.
Zheng L; Proteomics Groups, Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138668.
Bi X; Proteomics Groups, Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138668.
Chao SH; Expression Engineering and Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138668.

Oncotarget ; 7(5): 5483-94, 2016 Feb 02.

Article in En | MEDLINE | ID: mdl-26734838

Subject(s)

Apoptosis; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Peptide Fragments/pharmacology; RNA-Binding Proteins/metabolism; Blotting, Western; Breast Neoplasms/metabolism; Cell Proliferation; Female; Fluorescent Antibody Technique; Humans; RNA-Binding Proteins/antagonists & inhibitors; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53/genetics; Tumor Suppressor Protein p53/metabolism

Key words

HEXIM1; KLA; NPM; P-TEFb; p53

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Breast Neoplasms / RNA-Binding Proteins / Apoptosis Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Oncotarget Year: 2016 Type: Article

Fulltext

XML

PubMed Links

Search on Google